Australia explains rules for risk management plans
This article was originally published in SRA
Executive Summary
Drug companies in Australia are being advised to discuss with the Therapeutic Goods Administration the need for a risk management plan when they are planning their registration dossiers for certain types of prescription medicines1. The move is part of a new TGA initiative that requires RMPs to be submitted for applications for new chemical entities and significant extensions of indications, for example.